Patient empowerment and education by IT-supported pathways reduce postoperative pain intensity and rate of pain chronification after thoracic surgery

Patient empowerment and education by IT-supported pathways reduce postoperative pain intensity and rate of pain chronification after thoracic surgery - PEESURST

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00019087

Enrollment

1038

Registered

2022-12-22

Start date

2020-03-17

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

R52.2

Interventions

Group 1: Guideline-based pain therapy Group 2: Empowerment by the pain Nurse and IT-supported pathways

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Business-ready patients who are German and speak and understand the German language. Thoracotomy or VATS OP duration >30 min. Smartphone owner or internet access

Exclusion criteria

Exclusion criteria: Patients with contraindications to opioids or non-opioids estimated life expectancy of 1 year Addiction (except Nicotinabusus)

Design outcomes

Primary

Measure	Time frame
Reducing the incidence of chronical postthoracic pain syndrome and neuropathic pain is the primary objective. We will analyse the pain rate of the intervention group compared with the pain rate of the control group after 6 months. The pain rate is defined as a pain score over 0 (numeric rating scale 0-10).It is assumed that all patients with a pain score over 0 suffer from chronical postthoracic pain syndrome. Furthermore we analyse the rate of patients with neuropathic pain, which is detectable with the PainDETECT questionnaire. We collect the data of the PainDETECT preoperative and after 1, 3 and 6 months. It is assumed that all patients with a score over 18 suffer from neuropathic pain.	—

Measure

Time frame

Reducing the incidence of chronical postthoracic pain syndrome and neuropathic pain is the primary objective. We will analyse the pain rate of the intervention group compared with the pain rate of the control group after 6 months. The pain rate is defined as a pain score over 0 (numeric rating scale 0-10).It is assumed that all patients with a pain score over 0 suffer from chronical postthoracic pain syndrome. Furthermore we analyse the rate of patients with neuropathic pain, which is detectable with the PainDETECT questionnaire. We collect the data of the PainDETECT preoperative and after 1, 3 and 6 months. It is assumed that all patients with a score over 18 suffer from neuropathic pain.

—

Secondary

Measure	Time frame
Improvement of the quality of life, reducing the costs and cost effectiveness is the secondary objective. We will analyse the quality of life of the intervention group compared to the control group preoperative and after 1, 3 and 6 months with the questionnaires SF-12 and EQ-5D-5L. Furthermore we analyse the costs as well as the cost effectiveness (cost-effectiveness analysis and cost-benefit analysis) of the IT-supported clinical pathways as well as the patient empowerment/education compared to the standard pain therapy of the control group, which are insured at the AOK. The data include the expenses in the areas of inpatient care, out-patient medical care, pharmaceutical supply, supply of aids and rehabilitation. As clinical effect parameters we will use cases of non chronification (cost-effectiveness analysis) and the quality of life (cost-benefit analysis).	—

Measure

Time frame

Improvement of the quality of life, reducing the costs and cost effectiveness is the secondary objective. We will analyse the quality of life of the intervention group compared to the control group preoperative and after 1, 3 and 6 months with the questionnaires SF-12 and EQ-5D-5L. Furthermore we analyse the costs as well as the cost effectiveness (cost-effectiveness analysis and cost-benefit analysis) of the IT-supported clinical pathways as well as the patient empowerment/education compared to the standard pain therapy of the control group, which are insured at the AOK. The data include the expenses in the areas of inpatient care, out-patient medical care, pharmaceutical supply, supply of aids and rehabilitation. As clinical effect parameters we will use cases of non chronification (cost-effectiveness analysis) and the quality of life (cost-benefit analysis).

—

Countries

Germany

Contacts

Public ContactSandra Kampe

Universitätsmedizin Essen Ruhrlandklink Zentrum für Anästhesiologie und Schmerztherapie

Sekretariat.Anästhesie@ruhrlandklinik.uk-essen.de0201/433-4031

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026